<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38503660</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.</ArticleTitle><Pagination><StartPage>2475</StartPage><EndPage>2484</EndPage><MedlinePgn>2475-2484</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.01.103</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)00130-0</ELocationID><Abstract><AbstractText>Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E<sub>295</sub>K mutation as a showcase, we show that this technology can accurately detect E<sub>295</sub>K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E<sub>295</sub>K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 10<sup>7</sup> copies/µL to 1 × 10<sup>2</sup> copies/µL to achieve a linear correlation with R<sup>2</sup> &gt; 0.999, and PCR efficiencies of 95-105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R<sup>2</sup> of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E<sub>295</sub>K mutation levels between 0 % and 95 % (quantification range). In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Opmeer</LastName><ForeName>Lizet</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazzoli</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballmann</LastName><ForeName>Mónika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willemsen</LastName><ForeName>Marieke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voshol</LastName><ForeName>Gerben P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>GenomeScan B.V., Plesmanlaan 1d, 2333 BZ Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grudniewska-Lawton</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>GenomeScan B.V., Plesmanlaan 1d, 2333 BZ Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havenga</LastName><ForeName>Menzo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yallop</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamidi</LastName><ForeName>Ahd</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillissen</LastName><ForeName>Gert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Wilfried A M</ForeName><Initials>WAM</Initials><AffiliationInfo><Affiliation>Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL Leiden, The Netherlands. Electronic address: w.bakker@bataviabiosciences.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C477371">locked nucleic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011786" MajorTopicYN="N">Quality Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="Y">Oligonucleotides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AS LNA qPCR</Keyword><Keyword MajorTopicYN="N">Mutations</Keyword><Keyword MajorTopicYN="N">NGS</Keyword><Keyword MajorTopicYN="N">Quality control</Keyword><Keyword MajorTopicYN="N">Sabin Poliovirus 2</Keyword><Keyword MajorTopicYN="N">VP1-E295K</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">qPCR</Keyword><Keyword MajorTopicYN="N">sIPV</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>20</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>23</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38503660</ArticleId><ArticleId IdType="pmc">PMC11007389</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.01.103</ArticleId><ArticleId IdType="pii">S0264-410X(24)00130-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. Two out of three wild poliovirus strains eradicated: global eradication of wild poliovirus type 3 declared on World Polio Day; 2019. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated. Accessed 07-12.</Citation></Reference><Reference><Citation>Chard A.N., Datta S.D., Tallis G., Burns C.C., Wassilak S.G.F., Vertefeuille J.F., et al. Progress toward polio eradication - worldwide, January 2018-March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:784–789. doi: 10.15585/mmwr.mm6925a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6925a4</ArticleId><ArticleId IdType="pmc">PMC7316320</ArticleId><ArticleId IdType="pubmed">32584798</ArticleId></ArticleIdList></Reference><Reference><Citation>Centre for Disease Control and Prevention. Progress toward polio eradication — worldwide, January 2019–June 2021 | MMWR; 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389387</ArticleId><ArticleId IdType="pubmed">34437527</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G., Begg N.T., Cammack N., Minor P.D. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol. 1990;32:92–95. doi: 10.1002/jmv.1890320205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.1890320205</ArticleId><ArticleId IdType="pubmed">2177777</ArticleId></ArticleIdList></Reference><Reference><Citation>Laassri M., Lottenbach K., Belshe R., Rennels M., Plotkin S., Chumakov K. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis. 2006;193:1344–1349. doi: 10.1086/503366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/503366</ArticleId><ArticleId IdType="pubmed">16619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley E.B., Strauch C.B., Wieland-Alter W.F., Connor R.I., Lin S., Weiner J.A., et al. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217:371–380. doi: 10.1093/infdis/jix556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix556</ArticleId><ArticleId IdType="pmc">PMC5853416</ArticleId><ArticleId IdType="pubmed">29304199</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson K.M., Duintjer Tebbens R.J. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis. 2017;216:S176–S182. doi: 10.1093/infdis/jix108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix108</ArticleId><ArticleId IdType="pmc">PMC5853387</ArticleId><ArticleId IdType="pubmed">28838194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright P.F., Connor R.I., Wieland-Alter W.F., Hoen A.G., Boesch A.W., Ackerman M.E., et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16:1377–1384. doi: 10.1016/s1473-3099(16)30169-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(16)30169-4</ArticleId><ArticleId IdType="pmc">PMC5611465</ArticleId><ArticleId IdType="pubmed">27638357</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polioeradication Initiative. cVDPV2 Outbreaks and the type 2 novel oral polio vaccine (nOPV2); 2023. https://polioeradication.org/wp-content/uploads/2023/06/GPEI_nOPV2_Factsheet_31-May-2023.pdf. Accessed 09-01.</Citation></Reference><Reference><Citation>Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736–751.e738. doi: 10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt J.L., Campagnoli R., Vincent A., Shaw J., Wei L., Wynn N.T., et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. npj Vaccines. 2020;5:26. doi: 10.1038/s41541-020-0176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0176-7</ArticleId><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam A.J., Ferguson G., Stone D.M., Meredith J., Knowlson S., Auda G., et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol. 2006;80:8653–8663. doi: 10.1128/JVI.00370-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00370-06</ArticleId><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Roadmap for assessment of nOPV2 manufactured by PT Biofarma under the EUL procedure; 2020.</Citation></Reference><Reference><Citation>Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine. 2010;28:3778–3783. doi: 10.1016/j.vaccine.2010.02.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.02.095</ArticleId><ArticleId IdType="pubmed">20362626</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO technical report series No. 980, 2014, Annex 2; 2014.</Citation></Reference><Reference><Citation>Konz J.O., Schofield T., Carlyle S., Wahid R., Ansari A., Strating J., et al. Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. Vaccine X. 2021;8 doi: 10.1016/j.jvacx.2021.100102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2021.100102</ArticleId><ArticleId IdType="pmc">PMC8233139</ArticleId><ArticleId IdType="pubmed">34195600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker W.A., Thomassen Y.E., van't Oever A.G., Westdijk J., van Oijen M.G., Sundermann L.C., et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011;29:7188–7196. doi: 10.1016/j.vaccine.2011.05.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.05.079</ArticleId><ArticleId IdType="pubmed">21651934</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Mueller S., Chipman P.R., Bator C.M., Peng X., Bowman V.D., et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol. 2003;77:4827–4835. doi: 10.1128/jvi.77.8.4827-4835.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.8.4827-4835.2003</ArticleId><ArticleId IdType="pmc">PMC152153</ArticleId><ArticleId IdType="pubmed">12663789</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Cai W., Li J., Li Y., Yang X., Ma Y., et al. Evaluation of the genetic stability of Sabin strains and the consistency of inactivated poliomyelitis vaccine made from Sabin strains using direct deep-sequencing. Vaccine. 2019;37:130–136. doi: 10.1016/j.vaccine.2018.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.11.020</ArticleId><ArticleId IdType="pubmed">30467062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K.M. Molecular consistency monitoring of oral poliovirus vaccine and other live viral vaccines. Dev Biol Stand 1999;100:67–74. PMID: 10616177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K.M., Powers L.B., Noonan K.E., Roninson I.B., Levenbook I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci. 1991;88:199–203. doi: 10.1073/pnas.88.1.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.1.199</ArticleId><ArticleId IdType="pmc">PMC50777</ArticleId><ArticleId IdType="pubmed">1846038</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan H., Wahid R., Ansari A., Tritama E., Macadam A., Konz J., et al. Quantitative RT-PCR assays for quantification of undesirable mutants in the novel type 2 oral poliovirus vaccine. Vaccines (Basel) 2022;10 doi: 10.3390/vaccines10091394.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10091394</ArticleId><ArticleId IdType="pmc">PMC9502871</ArticleId><ArticleId IdType="pubmed">36146473</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Li J, Li CI, Long J, Samuels DC, Shyr Y. The effect of strand bias in Illumina short-read sequencing data. BMC Genomics. 2012 Nov 24;13:666. 10.1186/1471-2164-13-666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-13-666</ArticleId><ArticleId IdType="pmc">PMC3532123</ArticleId><ArticleId IdType="pubmed">23176052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezapkin G.V., Norwood L.P., Taffs R.E., Dragunsky E.M., Levenbook I.S., Chumakov K.M. Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control. Virology. 1995;211:377–384. doi: 10.1006/viro.1995.1420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1995.1420</ArticleId><ArticleId IdType="pubmed">7645242</ArticleId></ArticleIdList></Reference><Reference><Citation>Taffs R.E., Chumakov K.M., Rezapkin G.V., Lu Z., Douthitt M., Dragunsky E.M., et al. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology. 1995;209:366–373. doi: 10.1006/viro.1995.1268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1995.1268</ArticleId><ArticleId IdType="pubmed">7778271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R., Mercer L., Macadam A., Carlyle S., Stephens L., Martin J., et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. npj Vaccines. 2021;6:94. doi: 10.1038/s41541-021-00355-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00355-y</ArticleId><ArticleId IdType="pmc">PMC8322168</ArticleId><ArticleId IdType="pubmed">34326330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R., Mercer L., Gast C., De Leon T., Sáez-Llorens X., Fix A., et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. npj Vaccines. 2022;7:19. doi: 10.1038/s41541-022-00437-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00437-5</ArticleId><ArticleId IdType="pmc">PMC8837630</ArticleId><ArticleId IdType="pubmed">35149714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruijter J.M., Barnewall R.J., Marsh I.B., Szentirmay A.N., Quinn J.C., van Houdt R., et al. Efficiency correction is required for accurate quantitative PCR analysis and reporting. Clin Chem. 2021;67:829–842. doi: 10.1093/clinchem/hvab052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/hvab052</ArticleId><ArticleId IdType="pubmed">33890632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouritzen P., Nielsen A.T., Pfundheller H.M., Choleva Y., Kongsbak L., Møller S. Single nucleotide polymorphism genotyping using locked nucleic acid (LNA™) Expert Rev Mol Diagn. 2003;3:27–38. doi: 10.1586/14737159.3.1.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.3.1.27</ArticleId><ArticleId IdType="pubmed">12528362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota K., Ohashi A., Imachi H., Harada H. Improved in situ hybridization efficiency with locked-nucleic-acid-incorporated DNA probes. Appl Environ Microbiol. 2006;72:5311–5317. doi: 10.1128/AEM.03039-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.03039-05</ArticleId><ArticleId IdType="pmc">PMC1538721</ArticleId><ArticleId IdType="pubmed">16885281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Chen Z., Hou X., Li S., Zhu H., Qian J., et al. Locked nucleic acid pentamers as universal PCR primers for genomic DNA amplification. PLoS One. 2008;3 doi: 10.1371/journal.pone.0003701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003701</ArticleId><ArticleId IdType="pmc">PMC2577006</ArticleId><ArticleId IdType="pubmed">19002243</ArticleId></ArticleIdList></Reference><Reference><Citation>Latorra D., Campbell K., Wolter A., Hurley J.M. Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid (LNA) primers. Hum Mutat. 2003;22:79–85. doi: 10.1002/humu.10228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.10228</ArticleId><ArticleId IdType="pubmed">12815597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugozzoli L.A., Latorra D., Pucket R., Arar K., Hamby K. Real-time genotyping with oligonucleotide probes containing locked nucleic acids. Anal Biochem. 2004;324:143–152. doi: 10.1016/j.ab.2003.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2003.09.003</ArticleId><ArticleId IdType="pubmed">14654057</ArticleId></ArticleIdList></Reference><Reference><Citation>Radvánszka M., Paul E.D., Hajdu R., Boršová K., Kováčová V., Putaj P., et al. Sequential development of several RT-qPCR tests using LNA nucleotides and dual probe technology to differentiate SARS-CoV-2 from influenza A and B. J Microbial Biotechnol. 2022;15:1995–2021. doi: 10.1111/1751-7915.14031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.14031</ArticleId><ArticleId IdType="pmc">PMC9111289</ArticleId><ArticleId IdType="pubmed">35316574</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcila M., Lau C., Nafa K., Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011;13:64–73. doi: 10.1016/j.jmoldx.2010.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2010.11.005</ArticleId><ArticleId IdType="pmc">PMC3070595</ArticleId><ArticleId IdType="pubmed">21227396</ArticleId></ArticleIdList></Reference><Reference><Citation>Morandi L., de Biase D., Visani M., Cesari V., De Maglio G., Pizzolitto S., et al. Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation. PLoS One. 2012;7 doi: 10.1371/journal.pone.0036084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0036084</ArticleId><ArticleId IdType="pmc">PMC3340405</ArticleId><ArticleId IdType="pubmed">22558339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner S.N., Jaing C.J., Elsheikh M.M., Peña J., Hysom D.A., Borucki M.K. Multiplex degenerate primer design for targeted whole genome amplification of many viral genomes. Adv Bioinforma. 2014;2014 doi: 10.1155/2014/101894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/101894</ArticleId><ArticleId IdType="pmc">PMC4137498</ArticleId><ArticleId IdType="pubmed">25157264</ArticleId></ArticleIdList></Reference><Reference><Citation>Prout J., Tian M., Palladino A., Wright J., Thompson J.F. LNA blockers for improved amplification selectivity. Sci Rep. 2023;13:4858. doi: 10.1038/s41598-023-31871-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-31871-7</ArticleId><ArticleId IdType="pmc">PMC10038989</ArticleId><ArticleId IdType="pubmed">36964235</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod I.J., Rowley C.F., Essex M. PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens. Commun Biol. 2021;4:227. doi: 10.1038/s42003-021-01751-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01751-9</ArticleId><ArticleId IdType="pmc">PMC7892852</ArticleId><ArticleId IdType="pubmed">33603155</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>